ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

TBPH Theravance Biopharma Inc

9.12
-0.02 (-0.22%)
Apr 26 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 263,498
Bid Price 8.81
Ask Price 9.48
News -
Day High 9.27

Low
8.21

52 Week Range

High
11.98

Day Low 9.06
Share Name Share Symbol Market Stock Type
Theravance Biopharma Inc TBPH NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.02 -0.22% 9.12 23:00:02
Open Price Low Price High Price Close Price Previous Close
9.13 9.06 9.27 9.12 9.14
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
3,484 263,498 US$ 9.17 US$ 2,417,113 - 8.21 - 11.98
Last Trade Type Quantity Price Currency
15:13:44 17 US$ 9.12 USD

Theravance Biopharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
439.74M 48.16M - 57.42M -55.19M -1.15 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Theravance Biopharma News

Date Time Source News Article
4/10/202405:00PR Newswire (US)Theravance Biopharma, Inc. to Host Virtual Key Opinion..
2/26/202415:16Edgar (US Regulatory)Form 8-K - Current report
2/26/202415:05PR Newswire (US)Theravance Biopharma, Inc. Reports Fourth Quarter and Full..
2/22/202419:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/22/202419:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/22/202419:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/22/202419:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/22/202419:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
2/22/202405:00PR Newswire (US)Theravance Biopharma to Participate in an Upcoming Investor..
2/16/202419:12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of..
2/14/202415:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial..
2/14/202405:00PR Newswire (US)Theravance Biopharma to Report Fourth Quarter and Full Year..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TBPH Message Board. Create One! See More Posts on TBPH Message Board See More Message Board Posts

Historical TBPH Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week9.139.619.009.27351,605-0.01-0.11%
1 Month8.9910.448.759.37423,1420.131.45%
3 Months9.2410.448.219.02378,241-0.12-1.30%
6 Months9.2011.718.219.78389,518-0.08-0.87%
1 Year11.0911.988.219.96436,222-1.97-17.76%
3 Years21.1621.466.109.95690,101-12.04-56.90%
5 Years24.2831.546.1012.64546,580-15.16-62.44%

Theravance Biopharma Description

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. It develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Your Recent History

Delayed Upgrade Clock